A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons. Our principal product offerings are sold globally, primarily in the United States, Europe, Canada and Asia Pacific. We estimate that the annual worldwide market for peripheral vascular devices exceeds $9 billion, within which we estimate that the market for our products is approximately $1 billion. We sell our products and services primarily through a direct sales force.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 250M | 250M | 220M | 193M | 162M | 154M |
| Net Income | 58M | 58M | 44M | 30M | 21M | 27M |
| EPS | $2.52 | $2.52 | $1.93 | $1.34 | $0.93 | $1.25 |
| Free Cash Flow | 74M | 74M | 37M | 29M | 22M | 30M |
| ROIC | 9.5% | 93.9% | 17.0% | 10.8% | 8.4% | 14.9% |
| Gross Margin | 71.5% | 71.5% | 68.6% | 65.7% | 64.9% | 65.7% |
| Debt/Equity | 0.47 | 0.47 | 0.55 | 0.06 | 0.06 | 0.22 |
| Dividends/Share | $0.79 | $0.80 | $0.64 | $0.56 | $0.50 | $0.44 |
| Operating Income | 68M | 68M | 52M | 37M | 27M | 36M |
| Operating Margin | 27.2% | 27.2% | 23.8% | 19.0% | 16.6% | 23.6% |
| ROE | 14.7% | 15.8% | 13.9% | 10.6% | 7.9% | 12.6% |
| Shares Outstanding | 23M | 23M | 23M | 22M | 22M | 22M |
LEMAITRE VASCULAR INC passes 6 of 9 quality checks, suggesting mixed fundamentals.
LEMAITRE VASCULAR INC trades at 45.7x trailing earnings, compared to its 15-year median P/E of 39.0x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 35.2x vs a median of 34.9x. The company's 5-year average ROIC is 29.0% with a gross margin of 67.3%. Total shareholder yield (dividends) is 0.8%. At current prices, the estimated annualized return to fair value is +13.8%.
LEMAITRE VASCULAR INC (LMAT) has a current P/E ratio of 45.7, compared to its historical median P/E of 39.0. The stock is currently considered Fair based on its historical valuation range.
LEMAITRE VASCULAR INC (LMAT) has a 5-year average return on invested capital (ROIC) of 29.0%. This indicates strong capital allocation and a potential competitive advantage.
LEMAITRE VASCULAR INC (LMAT) has a market capitalization of $2.6B. It is classified as a mid-cap stock.
Yes, LEMAITRE VASCULAR INC (LMAT) pays a dividend with a trailing twelve-month yield of 0.69%. The company also returns capital through share buybacks, with a buyback yield of 0.07%.
Based on historical P/E analysis, LEMAITRE VASCULAR INC (LMAT) appears fair. The current P/E of 45.7 is 17% above its historical median of 39.0. The estimated fair value CAGR (P/E method) is 11.2%.
LEMAITRE VASCULAR INC (LMAT) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
LEMAITRE VASCULAR INC (LMAT) reported annual revenue of $250 million in its most recent fiscal year, based on SEC EDGAR filings.
LEMAITRE VASCULAR INC (LMAT) has a net profit margin of 23.1%. This is a strong margin indicating high profitability.
LEMAITRE VASCULAR INC (LMAT) generated $74 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
LEMAITRE VASCULAR INC (LMAT) has a debt-to-equity ratio of 0.47. This indicates a conservatively financed balance sheet.
LEMAITRE VASCULAR INC (LMAT) reported earnings per share (EPS) of $2.52 in its most recent fiscal year.
LEMAITRE VASCULAR INC (LMAT) has a return on equity (ROE) of 15.8%. This indicates the company generates strong returns for shareholders.
LEMAITRE VASCULAR INC (LMAT) has a 5-year average gross margin of 67.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for LEMAITRE VASCULAR INC (LMAT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LEMAITRE VASCULAR INC (LMAT) has a book value per share of $17.18, based on its most recent annual SEC filing.